期刊文献+

消化道癌P-糖蛋白的表达及与化疗反应的关系 被引量:1

P-glycoprotein expression in carcinoma of digestive tract and the role in chemotherapy
下载PDF
导出
摘要 目的:研究P糖蛋白(Pgp)在消化道常见癌组织中的表达,以指导临床化疗。方法:收集我院2002年1月~2002年10月术前未经治疗的消化道癌切除标本150例,以SP免疫组化方法检测其Pgp表达。结果:胃腺癌、大肠腺癌Pgp表达阳性率及强度均高于食管鳞癌,差异有统计学意义,P<0.01。Pgp阳性表达与消化道癌患者的性别、年龄、癌分化程度及淋巴结转移均无关,P>0.05。结论:Pgp在消化道常见癌组织中表达增高,检测消化道癌(尤其是胃肠道腺癌)的Pgp表达对选择合理的化疗方案和判断预后有重要作用。 OBJECTIVE: To ascertain the frequency of P-gtycoprotein (P-gp) expression in three, common carcinomas of digestive tract in order to direct elinical therapy.METHODS: One hundred and fifty surgically resected tumor specimens confirmed pathologically to be malignant digestive tract carcinomas from preoperatively untreated carcinoma patients were studied. Expression of P-gp was examined by SP immunohistochemistry. RESULTS: The positive rate and intensity of P-gp expression in gastric and colorectal adenocarcinomas were higher than those in squamous cell carcinoma of esophagus. the difference was significant,P〈0. 01, No correlation was observed with gender.age. differentiation and lymph node metastasis.P〉0. 05. CONCLUSIONS: Primary P-gp expression is related to the frequent occurrence in common carcinomas of digestive tract. Examining P-gp expression in digestive carcinomas, especially gastric and colorectal adenocarcinomas, plays an important role in orientating the cancer treatment and predicting prognosis.
出处 《肿瘤防治杂志》 CAS 2005年第17期1298-1299,共2页 China Journal of Cancer Prevention and Treatment
关键词 消化系统肿瘤/药物疗法 P-糖蛋白类/分析 药物耐药性 预后 digestive system neoplasmas drug therapy P-glycoproteins analysis drug tolerence prognosis
  • 相关文献

参考文献8

  • 1Grude P, Conti F, Mennecier D, et al. MDR1 gene expression in hep atocellular carcinoma and the peritumoral liver of patients with and without cirrhosis[J]. Cancer Lett, 2002,186(1):107-113.
  • 2Galani E, Sgouros J, Petropoulou C, et al. Correlation of MDR1, nm23-H1 and H Sema E gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patient[J]. Anticancer Res, 2002,22(4) :2275-2280.
  • 3Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistance cancer[J]. Curr Drug Targets, 2000,1(1):85-99.
  • 4Tada Y, Wada M, Migita T, et al. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin[J]. Int J Cancer,2002,98(4) :630-635.
  • 5Sutoh I, Kohno H, Nakashima Y, et al. Concurrent expression of metallothionein, glutathione S-transferase-pi, and P-glycoprotein in colorectal cancers[J]. Dis Colon Rectum, 2000, 43(2) :221-232.
  • 6Tokunaga Y, Hosogi H, Hoppon T, et al. Effects of MDR1/Pglycoprotein expression on prognosis in advanced colorectal cancer after surgery[J]. OncolRep, 2001,8(4):815-819.
  • 7Camassei F D, Arancia G, Cianfriglia M, et al. Nephroblastoma:multidrug resistance P-glycoprotein expression in tumor cell sand intratumoral capillary endotholial cells [J]. Am J Clin Pathol, 2002,117(3) :484-490.
  • 8Lacueva F J, Calpena R, Medrano J, et al. Changes in P-glycoprotein expression in gastril carcinoma with respect to distant gastric mucosa may be influenced by p53 [J]. Cancer, 2000,89(1) :21-28

同被引文献12

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部